Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting acinetobacter baumannii infections), zoliflodacin (targeting neisseria gonorrhoeae), and ETX0282CPDP (targeting enterobacteriaceae infections).

Entasis is also using its platform to develop a new class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins, targeting gram-negative infections.